(Q43921041)

28 November 2017

title

Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma (English)

1 reference

28 November 2017

Homayoun Shojamanesh

1

1 reference

28 November 2017

Fathia Gibril

2

1 reference

28 November 2017

Adeline Louie

3

1 reference

28 November 2017

Jeremiah V Ojeaburu

4

1 reference

28 November 2017

Showkat Bashir

5

1 reference

28 November 2017

Alaa Abou-Saif

6

1 reference

28 November 2017

Robert T Jensen

7

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

28 November 2017

1 reference

28 November 2017

volume

94

1 reference

28 November 2017

issue

2

1 reference

28 November 2017

page(s)

331-343

1 reference

Natural history of neuroendocrine enteropancreatic tumors

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Benign and malignant gastrinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Assessment and prediction of long-term cure in patients with the Zollinger-Ellison syndrome: the best approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Surgery to cure the Zollinger-Ellison syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Chemotherapy in the treatment of neuroendocrine malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Characterization of the in vivo and in vitro inhibition of gastrin secretion from gastrinoma by a somatostatin analogue (SMS 201-995).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Pancreatic endocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Mechanisms of antineoplastic action of somatostatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Antiproliferative effect of somatostatin and analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Treatment of type II gastric carcinoid tumors with somatostatin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Recent advances in diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Prospective study of chemotherapy in patients with metastatic gastrinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Zollinger-Ellison syndrome. Clinical presentation in 261 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Metastatic gastrinomas: localization with selective arterial injection of secretin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Distinguishing small hepatic hemangiomas from vascular liver metastases in gastrinoma: use of a somatostatin-receptor scintigraphic agent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Somatostatin receptor-dependent growth inhibition of liver metastases by octreotide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Slow-release lanreotide treatment in endocrine gastrointestinal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10195

7 January 2021

Identifiers

DOI

10.1002/CNCR.10195

1 reference

28 November 2017

1 reference